Since PTEN loss is observed in a large proportion of prostate tumors resulting in enhanced AKT activity [112], Hippo pathway inactivation via AKT is a likely event in the context of prostate cancer, which remains to be deeply explored. This evidence concerns the gene AKT1 and prostate neoplasm.